Nimotuzumab Combined With GX as Postoperative Adjuvant Therapy in Pancreatic Cancer
Status:
NOT_YET_RECRUITING
Trial end date:
2027-05-30
Target enrollment:
Participant gender:
Summary
This is a prospective, multicenter, randomized, double-blind, placebo-controlled study. The main purpose of the study is to evaluate the clinical efficacy and safety of Nimotuzumab combined with GX for postoperative adjuvant treatment of pancreatic cancer.
Phase:
PHASE2
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital